性别在系统性银屑病治疗中的作用：BIOBADADERM前瞻性队列研究中的处方、有效性及安全性差异
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort.
作者信息
Hernández-Fernández Carlos Pelayo, Carretero Gregorio, Rivera Raquel, Ferrándiz Carlos, Daudén Esteban, de Cueva Pablo, Belinchón Isabel, Gómez-García Francisco Javier, Herrera-Acosta Enrique, Ruiz-Genao Diana P, Ferrán Marta, Alsina Mercé, Baniandrés-Rodríguez Ofelia, Sánchez-Carazo José Luis, Botella-Estrada Rafael, Sahuquillo-Torralba Antonio, Rodríguez Lourdes, Vilar-Alejo Jaime, García-Donoso Carmen, Carrascosa José M, Llamas-Velasco Mar, Herrera-Ceballos Enrique, López-Estebaranz Jose Luis, Pujol-Marco Conrad, Descalzo Miguel Angel, Garcia-Doval Ignacio
机构信息
Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. E-mail:
出版信息
Acta Derm Venereol. 2021 Jan 4;101(1):adv00354. doi: 10.2340/00015555-3711.
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
性别对银屑病系统治疗的影响尚未得到充分研究。本研究的目的是分析一个来自西班牙的大型多中心队列，该队列包含2881例银屑病患者（男性占58.3%），随访时间为2008年1月至2018年11月，以确定性别是否会影响治疗方案的选择、治疗效果以及不良事件的风险。结果显示，女性比男性更有可能被处方使用生物制剂。就药物生存期衡量的治疗效果而言，男性和女性之间没有差异。女性更有可能发生不良事件，但风险差异较小，不足以说明需要采取不同的管理方式。研究的局限性包括残余混杂因素以及使用药物生存期作为疗效的替代指标。
Zotero 插件